Pemetrexed and Communicating Hydrocephalus

摘要

BackgroundPemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma of the lung. It is also approved for use in the maintenance setting as a single agent after patient completion of 4 to 6 cycles of a platinum-based doublet regimen for non–small cell lung cancer. With the increasing use of pemetrexed and longer durations of therapy, unexpected cumulative toxicity or other toxicities are possible.